ArticleIn vivo (Athens, Greece)
Spot Scanning Proton Beam Therapy for Surgery-inaccessible Hepatocellular Carcinoma: Preliminary Results.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Relationship Between Dose and Local Control in Five-fraction Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.In vivo (Athens, Greece)Article
- Modified Subtraction Technique for the Middle Hepatic Vein Tributary and Glissonean Pedicle in Right Lobe Graft Procurement.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimSpot scanning proton beam therapy (SS-PBT) was employed for the treatment of surgery-inaccessible hepatocellular carcinoma, primarily influenced by respiratory movement. PATIENTS AND
methodsBetween October 2022 and December 2023, 12 patients were enrolled in this study to evaluate the efficacy of SS-PBT. The median follow-up time was 13.1 months.
resultsThe one-year survival, progression-free survival, and local control rates were 79.5%, 57.1%, and 100%, respectively, without grade 2 or higher PBT-related toxicities. The clinical outcomes of these 12 patients appear comparable to data from prospective studies conducted at proton centers across Japan.
conclusionSS-PBT shows promise as a treatment option for surgery-inaccessible hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.